Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Catalyst Pharmaceuticals Long Term Debt 2011-2025 | CPRX

Catalyst Pharmaceuticals long term debt from 2011 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Catalyst Pharmaceuticals Annual Long Term Debt
(Millions of US $)
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Catalyst Pharmaceuticals Quarterly Long Term Debt
(Millions of US $)
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $2.800B $0.492B
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $83.859B 31.85
Zoetis (ZTS) United States $53.434B 19.12
Takeda Pharmaceutical (TAK) Japan $44.834B 9.15
Daiichi Sankyo, - (DSNKY) Japan $42.623B 21.23
BeOne Medicines - (ONC) Switzerland $41.395B 219.46
Sandoz Group AG (SDZNY) Switzerland $30.417B 0.00
United Therapeutics (UTHR) United States $19.872B 17.49
Merck (MKKGY) Germany $17.383B 11.30
Shionogi (SGIOY) Japan $14.751B 13.55
Neurocrine Biosciences (NBIX) United States $14.642B 35.13
Summit Therapeutics (SMMT) United States $14.521B 0.00
IPSEN (IPSEY) France $12.599B 0.00
Madrigal Pharmaceuticals (MDGL) United States $12.013B 0.00
Ionis Pharmaceuticals (IONS) United States $11.771B 0.00
Orion OYJ (ORINY) Finland $9.625B 27.50
Eisai (ESAIY) $8.295B 0.00
Corcept Therapeutics (CORT) United States $8.246B 89.08
Stevanato Group S.p.A (STVN) Italy $7.171B 40.14
Grifols, S.A (GRFS) Spain $5.975B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.204B 15.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.586B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $4.315B 0.00
Crinetics Pharmaceuticals (CRNX) United States $4.063B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $3.738B 17.76
Centessa Pharmaceuticals (CNTA) United Kingdom $3.575B 0.00
Hypermarcas (HYPMY) Brazil $3.161B 21.70
Procaps Group, S.A (PROCF) Luxembourg $2.926B 0.00
Dyne Therapeutics (DYN) United States $2.658B 0.00
Soleno Therapeutics (SLNO) United States $2.564B 0.00
Ocular Therapeutix (OCUL) United States $2.448B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.049B 24.28
Guardian Pharmacy Services (GRDN) United States $1.998B 38.48
Avadel Pharmaceuticals (AVDL) Ireland $1.859B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.512B 89.75
Collegium Pharmaceutical (COLL) United States $1.497B 7.41
Ardelyx (ARDX) United States $1.468B 0.00
Harrow (HROW) United States $1.424B 87.36
Amylyx Pharmaceuticals (AMLX) United States $1.354B 0.00
Xeris Biopharma Holdings (XERS) United States $1.259B 0.00
Enliven Therapeutics (ELVN) United States $1.202B 0.00
Oruka Therapeutics (ORKA) United States $1.176B 0.00
Nektar Therapeutics (NKTR) United States $1.173B 0.00
Evotec AG (EVO) Germany $1.115B 0.00
Relay Therapeutics (RLAY) United States $1.069B 0.00
Xencor (XNCR) United States $1.028B 0.00
Cronos Group (CRON) Canada $0.973B 0.00
Theravance Biopharma (TBPH) United States $0.895B 37.83
ARS Pharmaceuticals (SPRY) United States $0.884B 0.00
Organogenesis (ORGO) United States $0.822B 0.00
ProKidney (PROK) United States $0.789B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.725B 6.47
Esperion Therapeutics (ESPR) United States $0.724B 0.00
Elite Pharmaceuticals (ELTP) United States $0.717B 0.00
Savara (SVRA) United States $0.712B 0.00
Aquestive Therapeutics (AQST) United States $0.681B 0.00
KalVista Pharmaceuticals (KALV) United States $0.674B 0.00
Bioventus (BVS) United States $0.632B 12.97
4D Molecular Therapeutics (FDMT) United States $0.627B 0.00
Zevra Therapeutics (ZVRA) United States $0.529B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.505B 11.96
Lexeo Therapeutics (LXEO) United States $0.497B 0.00
Akebia Therapeutics (AKBA) United States $0.491B 0.00
Siga Technologies (SIGA) United States $0.445B 6.09
Altimmune (ALT) United States $0.441B 0.00
Galectin Therapeutics (GALT) United States $0.376B 0.00
Nature's Sunshine Products (NATR) United States $0.362B 21.55
USANA Health Sciences (USNA) United States $0.354B 9.89
Lyell Immunopharma (LYEL) United States $0.339B 0.00
Aldeyra Therapeutics (ALDX) United States $0.319B 0.00
Korro Bio (KRRO) United States $0.295B 0.00
Larimar Therapeutics (LRMR) United States $0.279B 0.00
Pyxis Oncology (PYXS) United States $0.272B 0.00
Aclaris Therapeutics (ACRS) United States $0.261B 0.00
Achieve Life Sciences (ACHV) Canada $0.251B 0.00
Journey Medical (DERM) United States $0.239B 0.00
AleAnna (ANNA) United States $0.230B 0.00
OmniAb (OABI) United States $0.226B 0.00
Protara Therapeutics (TARA) United States $0.205B 0.00
Heron Therapeutics (HRTX) United States $0.204B 0.00
Avalo Therapeutics (AVTX) United States $0.203B 0.00
MediWound (MDWD) Israel $0.202B 0.00
Profound Medical (PROF) Canada $0.195B 0.00
Innate Pharma SA (IPHYF) France $0.168B 0.00
Cassava Sciences (SAVA) United States $0.157B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.155B 0.00
China SXT Pharmaceuticals (SXTC) China $0.153B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.137B 0.00
Relmada Therapeutics (RLMD) United States $0.130B 0.00
Incannex Healthcare (IXHL) Australia $0.130B 0.00
Inhibikase Therapeutics (IKT) United States $0.121B 0.00
Avita Medical (RCEL) United States $0.115B 0.00
Surrozen (SRZN) United States $0.111B 0.00
Context Therapeutics (CNTX) United States $0.108B 0.00
Gain Therapeutics (GANX) United States $0.107B 0.00
Cardiol Therapeutics (CRDL) Canada $0.103B 0.00
Vivani Medical (VANI) United States $0.097B 0.00
Karyopharm Therapeutics (KPTI) United States $0.095B 0.00
Champions Oncology (CSBR) United States $0.095B 34.35
Unicycive Therapeutics (UNCY) United States $0.091B 0.00
Dominari Holdings (DOMH) United States $0.087B 0.00
VAXART, INC (VXRT) United States $0.087B 0.00
Assertio Holdings (ASRT) United States $0.083B 0.00
Prelude Therapeutics (PRLD) United States $0.083B 0.00
Plus Therapeutics (PSTV) United States $0.077B 0.00
PMV Pharmaceuticals (PMVP) United States $0.075B 0.00
Acrivon Therapeutics (ACRV) United States $0.072B 0.00
Lite Strategy (LITS) United States $0.072B 0.00
Nutriband (NTRB) United States $0.071B 0.00
Metagenomi (MGX) United States $0.070B 0.00
Rafael Holdings (RFL) United States $0.066B 0.00
Talphera (TLPH) United States $0.060B 0.00
BioNxt Solutions (BNXTF) Canada $0.060B 0.00
PolyPid (PYPD) Israel $0.060B 0.00
Fractyl Health (GUTS) United States $0.057B 0.00
NRx Pharmaceuticals (NRXP) United States $0.052B 0.00
Wellgistics Health (WGRX) United States $0.051B 0.00
Arch Biopartners (ACHFF) Canada $0.050B 0.00
Century Therapeutics (IPSC) United States $0.049B 0.00
ElectroCore (ECOR) United States $0.048B 0.00
Jupiter Neurosciences (JUNS) United States $0.048B 0.00
Telomir Pharmaceuticals (TELO) United States $0.046B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.040B 0.00
Tempest Therapeutics (TPST) United States $0.039B 0.00
Inotiv (NOTV) United States $0.038B 0.00
FibroGen (FGEN) United States $0.037B 0.00
Klotho Neurosciences (KLTO) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.036B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.036B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.032B 26.75
Liminatus Pharma (LIMN) United States $0.032B 0.00
Iterum Therapeutics (ITRM) Ireland $0.029B 0.00
Cosmos Health (COSM) United States $0.026B 0.00
SCYNEXIS (SCYX) United States $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.025B 0.00
Scienture Holdings (SCNX) United States $0.025B 0.00
Vyome Holdings (HIND) United States $0.019B 0.00
TherapeuticsMD (TXMD) United States $0.019B 0.00
Vivos Therapeutics (VVOS) United States $0.019B 0.00
Citius Pharmaceuticals (CTXR) United States $0.019B 0.00
Mangoceuticals (MGRX) United States $0.019B 0.00
Heatwurx (PCSA) United States $0.018B 0.00
Mannatech (MTEX) United States $0.018B 0.00
CASI Pharmaceuticals (CASI) China $0.018B 0.00
Natural Alternatives (NAII) United States $0.017B 0.00
Lipocine (LPCN) United States $0.016B 0.00
Traws Pharma (TRAW) United States $0.015B 0.02
BioLineRx (BLRX) Israel $0.015B 0.00
Ainos (AIMD) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.013B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.012B 0.00
BioVie (BIVI) United States $0.012B 0.00
ProPhase Labs (PRPH) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
VYNE Therapeutics (VYNE) United States $0.009B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Aptorum Group (APM) United Kingdom $0.008B 0.00
Biomerica (BMRA) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.007B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Nuvilex (PMCB) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
CDT Equity (CDT) United States $0.003B 0.00
Indaptus Therapeutics (INDP) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Indivior (INDV) United States $0.000B 15.36
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00